ZWINGENBERG, GERMANY - March 23, 2026 (NEWMEDIAWIRE) - BRAIN Biotech, a leading provider of specialist enzymes and innovative biological solutions for industry, announced today that the European ...

Microbes and fungi have long been nature's helpers in producing fine food, drinks and medicine, but new digital technologies could unlock far greater potential for the European biotech sector. Beer ...

DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS ...

In today’s fiercely competitive biotech industry, managing tight margins and evolving regulatory environments present major challenges. Add increased risks from geopolitical tensions, growing ...

Biotech stock Avalo Therapeutics (AVTX) skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment and a subsequent $375 million offering. The company tested its drug, ...

MaxCyte granted Legend Biotech a non-exclusive worldwide license to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform in connection with the research, clinical development, and ...

A new framework proposes matching specific financial instruments to three stages of biotechnological development, from early ...

A medical device company from Ireland, a biotech startup developing cancer therapeutics from Pennsylvania and a venture studio focused on women’s health from Massachusetts are among eight recipients ...

Biotechnology has figured prominently in recent Medicare coverage and payment policies. Biotech treatments push policy boundaries for several reasons: They attract strong patient demand; they often ...

Eupraxia Pharmaceuticals is developing clinical candidates that employ its DiffuSphere technology, which delivers treatments to the targeted tissues. The company's candidates are currently EP-104GI ...